Sunitinib-Induced Myositis Detected on 18F-FDG PET/CT

Clin Nucl Med. 2022 Mar 1;47(3):e311-e312. doi: 10.1097/RLU.0000000000004035.


Sunitinib is one of the most commonly used multikinase inhibitors for metastatic renal cell carcinoma. Myositis is one of the rarest known adverse effects of sunitinib. Presenting herewith one such case with its relevant imaging findings on FDG PET/CT and ultrasound.

MeSH terms

  • Carcinoma, Renal Cell* / diagnostic imaging
  • Carcinoma, Renal Cell* / drug therapy
  • Fluorodeoxyglucose F18
  • Humans
  • Kidney Neoplasms* / diagnostic imaging
  • Kidney Neoplasms* / drug therapy
  • Myositis* / chemically induced
  • Myositis* / diagnostic imaging
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography
  • Sunitinib / adverse effects


  • Fluorodeoxyglucose F18
  • Sunitinib